Department / Division:
Medicine / Cardiology

Address:
2424 Erwin Road, Suite 403
Durham, NC 27705

DUMC Box 2708
Durham, NC 27710

Appointment Telephone:
919-681-5816

Office Telephone:
919-668-8796

Fax Telephone:
919-668-7097

• MD, Johns Hopkins University School of Medicine (Maryland), 1978-1982

• Medicine, Barnes Hospital, Washington University, 1982-1985

• Cardiology, Duke University Medical Center, 1986-1988

Clinical Interests:
Coronary artery disease, coronary angioplasty, stent implantation, atherectomy, laser angioplasty, chronic total coronary occlusions, antiplatelet therapy, antithrombin therapy, clinical trials, information technology, medical informatics

Research Interests:
In addition to my clinical responsibilities as an interventional cardiologist, my research interests include 3 areas: clinical trials, in particular the new platelet glycoprotein IIb/IIIa integrin receptor antagonists, agents that prevent reperfusion injury, and drugs to prevent restenosis after angioplasty; computer databases; and ablative laser technology.

My research is applied (clinical research), primarily focusing on the evaluation of technologies in the clinical arena.

I have participated in numerous clinical trials and have also conducted several multicenter studies, including the EPIC, PROLOG, EPILOG, EPISTENT, IMPACT, IMPACT II, TOTAL, PRIDE, ESPRIT, MEND-1, and ELECT Trials.

My areas of expertise are an outgrowth of my clinical research, and includes use of the new antiplatelet therapeutics in the treatment of coronary artery disease; treatment of unstable angina and acute myocardial infarction; quality assurance and quality improvement; application of information technology to the delivery of care; and the application of excimer laser coronary angioplasty in the treatment of coronary artery disease.

Key words: angioplasty, excimer laser, platelet glycoproteins, computers, clinical trials.

Representative Publications:
The ESPRIT Investigators. The ESPRIT Study: A randomised, placebo-controlled trial of a novel dosing regimen of eptifibatide in planned coronary stent implantation. Lancet 356:2037-2044, 2000. (2000)

Tcheng JE, Lincoff AM, Sigmon KN, Lee KL, Kitt MM, Califf RM, Topol EJ, for the IMPACT-II Investigators. Randomised placebo-controlled trials of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT -II. Lancet 349:1422-28, 1997 May (1997)

Tcheng JE, Wells LD, Phillips HR, Deckelbaum LI, Golobic RA. Development of a new technique for reducing pressure pulse generation during 308-nm excimer laser coronary angioplasty. Cathet Cardiovasc Diagn. 34(1):15-22, 1995 Jan. (1995)

The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med. 330(14):956-61, 1994 Apr 7. (1994)

Tcheng JE, Ellis SG, George BS, Kereiakes DJ, Kleiman NS, Talley JD, Wang AL, Weisman HF, Califf RM, Topol EJ. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation. 90(4):1757-64, 1994 Oct. (1994)